How Long Does the Allergy Shot Last? Steroid Shots vs. Immunotherapy Explained

A Kenalog shot is a brand name for triamcinolone acetonide, an intramuscular corticosteroid injection administered by many primary care physicians and some allergists for severe seasonal allergy flares. The corticosteroid is slowly released from the muscle into the bloodstream over several days, producing broad anti-inflammatory suppression that reduces allergy symptoms within 24-48 hours. The duration of effect typically ranges from 2-6 weeks, depending on dose and individual metabolism. Kenalog does not modify the immune response to allergens — it suppresses immune reactivity systemically while the drug is active, and symptoms return when the drug clears. AAAAI and ACAAI guidelines (Dykewicz et al., JACI 2020) explicitly state that intramuscular corticosteroid injections should not be used as routine management of allergic rhinitis because the risk-benefit profile does not justify regular use when safer effective alternatives exist.

The caution against annual steroid shots (Kenalog) for hay fever refers to the cumulative side effects of repeated systemic corticosteroid exposure, not to allergen immunotherapy. With repeated intramuscular steroid injections, the hypothalamic-pituitary-adrenal (HPA) axis can become suppressed, reducing the body's own cortisol production — an effect documented with as few as 2-3 annual injections over several years (Buchman, Semin Arthritis Rheum 2001). Additional cumulative risks include decreased bone mineral density (leading to osteoporosis with repeated exposure), avascular necrosis of the hip, glucose dysregulation (particularly concerning for pre-diabetic or diabetic patients), weight gain, and skin thinning. AAAAI and ACAAI guidelines recommend intranasal corticosteroid sprays as the preferred steroid delivery method for allergic rhinitis — they provide comparable or superior symptom control with minimal systemic absorption and none of the cumulative systemic risks of intramuscular injections.

Immunotherapy and steroid shots differ in mechanism, risk profile, timing, and long-term outcome. A steroid injection introduces a corticosteroid drug into the body, producing broad immune suppression for 2-6 weeks with immediate symptom relief but no lasting immune change. An immunotherapy injection introduces a small dose of the actual allergen that causes your allergy — starting at an extremely low concentration and increasing gradually over months — to retrain your immune system to tolerate that allergen. Steroid shots work immediately and wear off completely; immunotherapy takes months to produce noticeable benefit but can produce lasting disease modification for 3-12 years after a completed course (Durham et al., NEJM 1999). Repeated steroid injections carry cumulative systemic risks including adrenal suppression and osteoporosis; repeated immunotherapy injections do not produce cumulative systemic toxicity. The treatment philosophies are fundamentally opposite: suppression versus education of the immune system.

Completing a full 3-5 year course of allergen immunotherapy produces disease-modifying immunity that may persist for 3-12 years after stopping injections. The landmark evidence comes from Durham et al. (NEJM 1999), who showed that patients who completed 3-4 years of grass pollen SCIT maintained symptom and medication scores as low as those still on active treatment for at least 3 years post-discontinuation. The longest available follow-up data is from Eng et al. (Allergy 2006), who reported that a childhood grass pollen SCIT cohort maintained significantly lower symptom scores and medication use 12 years after stopping treatment. Duration of post-treatment benefit is related to total treatment duration — patients who complete 3 or more years consistently show more durable benefit than those who stop at 2 years. Pediatric patients may also experience an additional benefit: prevention of new allergen sensitizations and reduced risk of progressing from rhinitis to asthma, effects documented at 10-year follow-up in the PAT study (Jacobsen et al., Allergy 2007).

Based on current AAAAI and ACAAI guidelines, annual intramuscular corticosteroid injections are not recommended for routine seasonal allergy management. The 2020 Rhinitis Practice Parameter (Dykewicz et al., JACI 2020) explicitly states that intramuscular depot corticosteroids should not be used for routine treatment of allergic rhinitis due to their systemic side effect profile. The risks of repeated seasonal use include HPA axis suppression reducing the body's natural cortisol production, decreased bone density over years, and glucose dysregulation. A single Kenalog injection for a particularly severe flare — when other medications have failed and symptoms are debilitating — may be appropriate in specific situations, at the discretion of your physician. But substituting annual steroid shots for evidence-based seasonal management (intranasal steroids, antihistamines, leukotriene antagonists, immunotherapy) is not aligned with current clinical guidelines. If your seasonal symptoms are severe enough to warrant considering steroid shots each year, that severity is itself a strong argument for allergen immunotherapy, which would modify the underlying disease rather than suppress it annually.